NTLA FY 2017 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

FY 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$26M+58.5% YoY

Gross Profit

-$42M-159.0% margin

Operating Income

-$70M-266.3% margin

Net Income

-$68M-258.6% margin

EPS (Diluted)

$-1.88

Cash Flow

Operating Cash Flow

-$65M

Free Cash Flow

-$75M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$376M

Total Liabilities

$76M

Stockholders' Equity

$301M

Cash & Equivalents

$341M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$16M	+58.5%
Gross Profit	-$42M	-$15M	-170.4%
Operating Income	-$70M	-$32M	-116.3%
Net Income	-$68M	-$32M	-113.5%